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In a muscle biopsy based study, only 9 out of 5450 biopsy samp-
les, received from all parts of greater Istanbul area, had typical 
clinical and most suggestive light microscopic sporadic-inclusion 
body myositis (s-IBM) findings. Two other patients with and ten 
further patients without characteristic light microscopic findings 
had referring diagnosis of s-IBM. As the general and the age-
adjusted populations of Istanbul in 2010 were 13.255.685 and 
2.347.300 respectively, the calculated corresponding ‘estimated 
prevalences’ of most suggestive s-IBM in the Istanbul area we-
re 0.679 X 10-6 and 3.834 X 10-6. Since Istanbul receives heavy 
migration from all regions of Turkey and ours is the only muscle 
pathology laboratory in Istanbul, projection of these figures to 
the Turkish population was considered to be reasonable and an 
estimate of the prevalence of s-IBM in Turkey was obtained. 
The  calculated  ‘estimated  prevalence’  of  s-IBM  in  Turkey  is 
lower than the previously reported rates from other countries. 
The wide variation in the prevalence rates of s-IBM may reflect 
different genetic, immunogenetic or environmental factors in dif-
ferent populations.
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Introduction
Although s-IBM is recognized as the most prevalent 
acquired myopathy in patients over age 50 years (1-3), 
population studies reporting the incidence or prevalence 
rates are very few. Population studies in Caucasian popu-
lations of North America, Northern Europe and Western 
Australia show high general and age-adjusted prevalence 
rates (3-7). Furthermore, it is strongly affirmed by some 
authors that the condition is underdiagnosed (2, 3, 7, 8). 
On the other hand, observation that s-IBM is rare in Israel 
and Sicily (Italy) has been reported as personal commu-
nication (2, 3). As we had a similar observation in our 
population  and  also  as  the  Neuromuscular  Pathology 
Laboratory of Istanbul University is the only adequate 
neuromuscular pathology laboratory in Istanbul receiving 
muscle and nerve biopsies from all parts of greater Istan-
bul, with an average of 400-450 muscle biopsies annually, 
we aimed at calculating the ‘estimated prevalence’ of s-
IBM in Istanbul/Turkey. 
Materials and methods
All muscle biopsies were reviewed by the same aut-
hor (P.SO) who had been trained to search for s-IBM. 
Fifty percent of the muscle biopsies were from the Neu-
romuscular Clinic and 10% were from the Rheumatology 
and Pediatric Neurology Clinics of Istanbul University. A 
further 40% of the biopsies was sent by different hospitals 
from all parts of Istanbul. The study is based on muscle 
biopsies which had been received by the Neuromuscular 
Pathology Laboratory between 1993 (the main establis-
hment  of  the  laboratory)  and  2011.The  corresponding 
biopsy request forms were the used as the source of the 
clinical information of the patients. A total of 5450 musc-
le biopsies, 673 from individuals at or over age 50 years 
were considered. In order to include the possible uncom-
mon presentations, biopsies belonging to individuals with 
clinical onset at or over age 30 years were selected among 
this group. Thus, 533 biopsies and their available clinical 
data were included in the study. 
As Amyloid β, SMI-31 and MHC-1 immunocyto-
chemistry were not available in the former years, these 
parameters were not considered in the classification of 
the  cases.  Electron  microscopy  is  still  not  performed 
routinely. In the absece of amyloid β or SMI-31 immu-
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nocytochemistry  and  electron  microscopic  study,  the 
recognized diagnostic criteria were not used and the 
term ‘most suggestive’ instead of ‘definite’ was used to 
describe s-IBM pathology (9). In order to prevent un-
der-estimation,  patients  with  typical  symptoms/signs 
but only suggestive light microscopic findings, and the 
ones with biopsies without inflammation and vacuo-
les but with clinical working diagnoses of s-IBM were 
also considered. Typical symptoms/signs were defined 
as longstanding distal weakness or quadriceps femoris 
muscle involvement. 
The patients were grouped in the following order: 
Group A) Most suggestive s-IBM 
Specimen:  Light  microscopic  s-IBM  (endomysial 
inflammation + intracellular red-rimmed vacuoles + con-
siderable COX(-) fibers) 
Request form: Typical symptoms/signs of s-IBM, 
Group B) Probable s-IBM 
Specimen: Suggestive light microscopic s-IBM (va-
cuolated fibers without any inflammation or 1-2 vacuoles 
with necrosis) 
Request form: Typical symptoms/signs of s-IBM, 
Group C) Questionable s-IBM 
Specimen: Not suggesting s-IBM 
Request form: May not sug-
gest s-IBM but has working diag-
nosis as s-IBM. 
All  included  biopsy  slides 
were re-evaluated by one of the 
authors (PS).
As Istanbul University Neu-
romuscular  Pathology  Labora-
tory is the only laboratory which 
gives  service  to  all  hospitals  in 
Istanbul, our numbers were pro-
jected to calculate the ‘estimated 
prevalence’ of s-IBM in Istanbul. 
Population of Istanbul was obtai-
ned from the population projecti-
on data of the Turkish Statistical 
Institute  (TURKSTAT)  of  the 
Government of Turkey.
General  and  age-adjusted 
frequencies of Group A, Groups 
A+B  and  Groups A+B+C  were 
calculated  (per  million)  for  the 
total population and for the popu-
lation adjusted for age over 50. 
Results
The  general  population 
and the population over age 50 
of Istanbul at 2010 census given by TURKSTAT were 
13.255.685 and 2.347.300 respectively.
Based on our definition, 9 patients qualified for most 
suggestive s-IBM diagnosis (Group A). This gave a calcu-
lated general prevalence of 0.679 X 10-6 and age adjusted 
prevalence of 3.834 X 10-6 for the Istanbul area. In order 
to prevent under-diagnosis, patients with probable s-IBM 
(Group B), a total of 5 patients, were also considered. The 
sum of groups A and B gave a prevalence rate of 1.056 X 
10-6 and age adjusted prevalence of 5.964 X 10-6. Eleven 
other patients had questionable s-IBM. Patient numbers 
in groups A, B and C, and prevalence rates in groups A, 
A+B and A+B+C are given in Table 1.
When the most suggestive s-IBM group was divided 
into periods of 1993-1999, 2000-2005 and 2005-2010 the 
numbers of patients were 2, 3 and 4 respectively.
Since Istanbul receives heavy migration from all re-
gions of Turkey and ours is the only muscle pathology 
laboratory in Istanbul, projection of these figures to the 
Turkish population was considered to be reasonable and 
an estimate of the prevalence of s-IBM in Turkey was ob-
tained.
Figure 1. A) Atrophy of the long finger flexors and inability to flex the fingers 
in one of our patients with typical clinical findings of s-IBM. B) Inflammation and 
rimmed vacuoles in one of our patients with most suggestive s-IBM histopathol-
ogy (Engel’s modified trichrome (E-MGT) stain, 250X) C) Inflammation and rimmed 
vacuoles in higher magnification in one of our patients with most suggestive s-IBM 
histopathology (E-MGT stain, 500X) D) Sarcolemmal MHC-1 staining in most fibers 
in the same patient (500X).P. Serdaroglu et al.
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Discussion
Estimated prevalence and age adjusted prevalence ra-
tes of s-IBM in Istanbul/Turkey are found to be far lower 
than those in the previously reported population studies. 
This low prevalence rate could be explained by the unfa-
miliarity of the clinicians and the pathologist interpreting 
the biopsy data. Although this is a possibility, the patholo-
gist had been trained to search for s-IBM and attempts of 
raising clinician awareness have been made at the national 
meetings since 1991. Another explanation could be the 
differing availability of medical investigations and diffe-
ring tendencies to seek medical advice in case of musc-
le weakness among older people between countries. To 
overcome this obstacle, we divided the number of most 
suggestive group A patients into different periods. When 
the latest period of 2005-end-of-2010 was considered, the 
‘estimated prevalence’ rates were still very low. 
The low prevalence persisted even when groups A 
and B and further when all groups were merged (Group 
A+B+C) in order to prevent underestimation of s-IBM di-
agnosis. The comparison of our rates with the previously 
reported population studies on the ‘estimated prevalence’ 
of s-IBM is given in Table 1 (3-7). 
This is the first attempt to study the estimated preva-
lence rate in a biopsy based manner in a Mediterranean 
country on the ‘estimated prevalence’ of s-IBM and it 
confirms unpublished observations from this region (2) 
and from a study in France in which, although not popu-
lation based, the frequency of IBM was found to be 0.6 
among 850 muscle biopsies (10).
Our findings show that prevalence of s-IBM varies 
greatly among countries and that this variation may be 
due to genetic, immunogenetic and/or environmental fa-
ctors. 
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Table 1. General and age adjusted prevalence rates of s-IBM in Istanbul/Turkey and their comparison with the rates 
in previous reports.
Present sudy Prevıous populatıon studıes
Group
A*
Group
A+B**
Group
A+B+C***
Netherlands(3) Western Australıa(5, 2) USA(6)
(Conncticut) 
(Age >45)
Authors This study Badrising
et al. (2000)
Phillips
et al. (2000)
(Needham et al. (2008))
Felice
(2001)
Prevalence 
(X10-6)
0.7
(0.679)
1.0
(1.056)
1.9
(1.886)
4.9 4.3
(14.9)
10.7
Age Adjusted 
Prevalence 
(X10-6)
3.8
(3.834)
6
(5.964)
10.7
(10.651)
16.0 35.3
(51.2)
28.9
*Group A: Most suggestive s-IBM, **Group B: Probable s-IBM, ***Group C: Suspicious s-IBM